Table 6 Subgroup analyses of recurrence/disease/progress-free survival
Subgroup | NO. of studies | HR (95% CI) | P | Heterogeneity | Model | |
|---|---|---|---|---|---|---|
I2 (%) | Ph | |||||
Cancer type | ||||||
RCC | 4 | 1.96 (1.44–2.66) | < 0.001 | 0.0 | 0.636 | Fixed |
UC | 3 | 1.42 (1.18–1.71) | < 0.001 | 0.0 | 0.483 | Fixed |
Cancer stage | ||||||
Non-metastatic | 5 | 1.61 (1.32–1.97) | < 0.001 | 29.2 | 0.227 | Fixed |
Metastatic | 2 | 2.65 (1.19–5.90) | 0.017 | 0.0 | 0.372 | Fixed |
Mixed | 1 | 1.43 (1.10–1.86) | 0.008 | – | – | – |
Treatment | ||||||
Surgery | 7 | 1.57 (1.34–1.84) | < 0.001 | 29.6 | 0.202 | Fixed |
Target therapy | 1 | 1.91 (0.65–5.61) | 0.239 | – | – | – |
Sample size | ||||||
> 400 | 4 | 1.49 (1.25–1.77) | < 0.001 | 36.5 | 0.193 | Fixed |
< 400 | 4 | 2.12 (1.43–3.15) | < 0.001 | 0.0 | 0.716 | Fixed |
Cuf-off | ||||||
3 | 4 | 1.54 (1.22–1.94) | < 0.001 | 36.6 | 0.192 | Fixed |
≤ 2 | 4 | 1.61 (1.30–1.99) | < 0.001 | 21.9 | 0.279 | Fixed |
Population | ||||||
Asian | 7 | 1.53 (1.30–1.79) | < 0.001 | 0.0 | 0.487 | Fixed |
African | 1 | 3.09 (1.45–6.59) | 0.003 | – | – | – |